Azacitidine, a therapeutic option in Lewis and Sumner syndrome associated with VEXAS syndrome

Rev Neurol (Paris). 2022 Dec;178(10):1109-1111. doi: 10.1016/j.neurol.2022.06.008. Epub 2022 Nov 8.
No abstract available

Publication types

  • Letter

MeSH terms

  • Azacitidine* / therapeutic use
  • Humans
  • Neural Conduction
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating*
  • Syndrome

Substances

  • Azacitidine

Supplementary concepts

  • VEXAS syndrome